NASDAQ: KRBPKiromic Biopharma Inc Stock
$0.38+0.12 (+46.15%)
Updated Sep 23, 2022
KRBP Price
$0.38
Fair Value Price
$0.79
Market Cap
$5.94M
52 Week Low
$0.23
52 Week High
$3.53
P/E
-0.17x
P/B
0.5x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$32.56M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.66
Operating Cash Flow
-$28M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Score
–
Industry Average (29)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how KRBP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
KRBP ($0.38) is undervalued by 52.46% relative to our estimate of its Fair Value price of $0.79 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
KRBP ($0.38) is significantly undervalued by 52.46% relative to our estimate of its Fair Value price of $0.79 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
KRBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more KRBP due diligence checks available for Premium users.
Be the first to know about important KRBP news, forecast changes, insider trades & much more!
KRBP News
Valuation
KRBP fair value
Fair Value of KRBP stock based on Discounted Cash Flow (DCF)
Price
$0.38
Fair Value
$0.79
Undervalued by
51.83%
KRBP ($0.38) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
KRBP ($0.38) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
KRBP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
KRBP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.17x
Industry
15.88x
Market
27.65x
KRBP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.5x
Industry
4.31x
KRBP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
KRBP's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.4M
Profit Margin
0%
KRBP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$19.5M
Liabilities
$7.7M
Debt to equity
0.66
KRBP's short-term assets ($8.03M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
KRBP's short-term assets ($8.03M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
KRBP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$6.0M
Investing
-$2.5M
Financing
-$170.8k
KRBP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
KRBP vs Biotech Stocks
Kiromic Biopharma Stock FAQ
©2022 WallStreetZen
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.